Lilly Opens Phase 3 Clinical Trial for Selpercatinib (LOXO-292) in RET-Mutant Medullary Thyroid CancerFukushima Nuclear Disaster | Increased Thyroid Cancer in U.S. This evidence concerns the gene RET and thyroid cancer.